過敏性腸症候群（IBS）治療薬市場2020：地域の見通し（アメリカ、ヨーロッパ、アジア太平洋、中東、アフリカ）別のサイズ、業界分析レポート、成長の可能性、価格動向、競争力のある市場シェア、市場統計と予測2020-2025 (アップデート版あり)

このレポートには、最新の市場図、統計、データが含まれています

ライセンスを選択

概要
目次

IBSは、ローマIII基準によると、少なくとも3か月間、腸機能の変化に伴う腹痛または不快感を特徴とする慢性障害です。患者はしばしば症状の再発を経験します。
まとめグローバル過敏性腸症候群（IBS）治療薬市場は、2015年から2019年までのCAGR xx％でxxx百万米ドルと評価されました。その後、2020年にはXXX百万米ドルに達し、2020年から2025年までのCAGRはxx％になります。

世界の過敏性腸症候群（IBS）治療薬市場では、このレポートは特に北アメリカ、南アメリカ、ヨーロッパとアジア太平洋、および中東とアフリカに焦点を当てています。このレポートは、アプリケーション、タイプ、地域、および製造業者に基づいて市場を分類します。

メーカー別の市場細分化では、レポートは次の企業をカバーしています-
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Valeant Pharmaceuticals International
Ardelyx
Astellas Pharma
Novartis
GlaxoSmithKline
Ironwood Pharmaceuticals

地理的地域による市場細分化では、レポートは次の地域を分析しました-
北米（米国、カナダ、メキシコ）
ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
アジア太平洋（中国、日本、韓国、インド、東南アジア）
南アメリカ（ブラジル、アルゼンチン、コロンビアなど）
中東およびアフリカ（サウジアラビア、アラブ首長国連邦、エジプト、ナイジェリア、南アフリカ）

タイプによる市場細分化：
Blautix（株）
Bekinda（IBS-D）
SYN-010
Tenapanor
アプリケーションによる市場細分化：
病院
研究
この調査は、次の重要な質問に対する回答を提供します。
• 2020年から2025年の予測期間における過敏性腸症候群（IBS）治療薬市場の推定成長率と市場シェアおよび規模はどのくらいですか？
• 予測期間2020年から2025年の過敏性腸症候群（IBS）治療薬市場の原動力は何ですか？
• 著名なマーケットプレーヤーは誰ですか？彼らは他の競合他社に対してどのように競争力を獲得しましたか？
• 世界中の過敏性腸症候群（IBS）治療薬の業界の進歩に影響を与える市場動向は何ですか？
• 業界の進歩を制限する主な課題と脅威は何ですか？
• 市場は著名な市場プレーヤーにとってどのような機会を持っていますか？
このレポートに関する特別な要件がある場合は、お知らせください。カスタムレポートを提供できます。

注–より正確な市場予測を提供するために、COVID-19の影響を考慮して、すべてのレポートが配信前に更新されます。

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size Growth Rate by Type (2020-2025)
1.3.2 Blautix (Strain)
1.3.3 Bekinda (IBS-D)
1.3.4 SYN-010
1.3.5 Tenapanor
1.4 Market Segment by Application
1.4.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Share by Application (2020-2025)
1.4.2 Hospital
1.4.3 Research
1.5 Study Objectives
1.6 Years Considered

2 Global Growth Trends
2.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size
2.1.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue 2015-2025
2.1.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales 2015-2025
2.2 Irritable Bowel Syndrome (IBS) Therapeutics Growth Rate by Regions
2.2.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales by Regions 2015-2019
2.2.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Regions 2015-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers

3 Market Share by Manufacturers
3.1 Irritable Bowel Syndrome (IBS) Therapeutics Sales by Manufacturers
3.1.1 Irritable Bowel Syndrome (IBS) Therapeutics Sales by Manufacturers 2015-2019
3.1.2 Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Manufacturers 2015-2019
3.2 Revenue by Manufacturers
3.2.1 Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Manufacturers (2015-2019)
3.2.2 Irritable Bowel Syndrome (IBS) Therapeutics Revenue Share by Manufacturers (2015-2019)
3.2.3 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.3 Irritable Bowel Syndrome (IBS) Therapeutics Price by Manufacturers
3.4 Key Manufacturers Irritable Bowel Syndrome (IBS) Therapeutics Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Irritable Bowel Syndrome (IBS) Therapeutics Market
3.6 Key Manufacturers Irritable Bowel Syndrome (IBS) Therapeutics Product Offered
3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Blautix (Strain) Sales and Revenue (2015-2019)
4.1.2 Bekinda (IBS-D) Sales and Revenue (2015-2019)
4.1.3 SYN-010 Sales and Revenue (2015-2019)
4.1.4 Tenapanor Sales and Revenue (2015-2019)
4.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Type
4.3 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue Market Share by Type
4.4 Irritable Bowel Syndrome (IBS) Therapeutics Price by Type

5 Market Size by Application
5.1 Overview
5.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales by Application

6 United States
6.1 United States Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Company
6.2 United States Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Type
6.3 United States Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Application

7 European Union
7.1 European Union Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Company
7.2 European Union Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Type
7.3 European Union Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Application

8 China
8.1 China Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Company
8.2 China Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Type
8.3 China Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Application

9 Rest of World
9.1 Rest of World Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Company
9.2 Rest of World Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Type
9.3 Rest of World Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Application
9.4 Rest of World Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by Countries
9.4.1 Rest of World Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries
9.4.2 Rest of World Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia

10 Company Profiles
10.1 Abbott Laboratories
10.1.1 Abbott Laboratories Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Irritable Bowel Syndrome (IBS) Therapeutics
10.1.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Introduction
10.1.5 Abbott Laboratories Recent Development
10.2 Synergy Pharmaceuticals
10.2.1 Synergy Pharmaceuticals Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Irritable Bowel Syndrome (IBS) Therapeutics
10.2.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Introduction
10.2.5 Synergy Pharmaceuticals Recent Development
10.3 Sucampo Pharmaceuticals
10.3.1 Sucampo Pharmaceuticals Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Irritable Bowel Syndrome (IBS) Therapeutics
10.3.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Introduction
10.3.5 Sucampo Pharmaceuticals Recent Development
10.4 Valeant Pharmaceuticals International
10.4.1 Valeant Pharmaceuticals International Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Irritable Bowel Syndrome (IBS) Therapeutics
10.4.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Introduction
10.4.5 Valeant Pharmaceuticals International Recent Development
10.5 Ardelyx
10.5.1 Ardelyx Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Irritable Bowel Syndrome (IBS) Therapeutics
10.5.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Introduction
10.5.5 Ardelyx Recent Development
10.6 Astellas Pharma
10.6.1 Astellas Pharma Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Irritable Bowel Syndrome (IBS) Therapeutics
10.6.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Introduction
10.6.5 Astellas Pharma Recent Development
10.7 Novartis
10.7.1 Novartis Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Irritable Bowel Syndrome (IBS) Therapeutics
10.7.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Introduction
10.7.5 Novartis Recent Development
10.8 GlaxoSmithKline
10.8.1 GlaxoSmithKline Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Irritable Bowel Syndrome (IBS) Therapeutics
10.8.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Introduction
10.8.5 GlaxoSmithKline Recent Development
10.9 Ironwood Pharmaceuticals
10.9.1 Ironwood Pharmaceuticals Company Details
10.9.2 Company Description and Business Overview
10.9.3 Sales, Revenue and Market Share of Irritable Bowel Syndrome (IBS) Therapeutics
10.9.4 Irritable Bowel Syndrome (IBS) Therapeutics Product Introduction
10.9.5 Ironwood Pharmaceuticals Recent Development

11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Irritable Bowel Syndrome (IBS) Therapeutics Sales Channels
11.2.2 Irritable Bowel Syndrome (IBS) Therapeutics Distributors
11.3 Irritable Bowel Syndrome (IBS) Therapeutics Customers

12 Market Forecast
12.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales and Revenue Forecast 2020-2025
12.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Forecast by Type
12.3 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Forecast by Application
12.4 Irritable Bowel Syndrome (IBS) Therapeutics Forecast by Regions
12.4.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Forecast by Regions 2020-2025
12.4.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue Forecast by Regions 2020-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India

13 Research Findings and Conclusion

14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer